Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer

Abstract Background The global Phase III IMpower132 study evaluating atezolizumab plus pemetrexed and carboplatin or cisplatin (APP) versus pemetrexed plus carboplatin or cisplatin (PP) for first‐line treatment of non‐squamous advanced non‐small cell lung cancer (NSCLC) met its co‐primary progressio...

Full description

Bibliographic Details
Main Authors: Shun Lu, Jian Fang, Ziping Wang, Yun Fan, Yunpeng Liu, Jianxing He, Jianying Zhou, Jie Hu, Jinjing Xia, Wenxin Liu, Jane Shi, Jing Yi, Lejie Cao
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
chemotherapy
China
non‐small cell lung cancer
PD‐L1 inhibitor
PD‐L1 protein
Online Access:https://doi.org/10.1002/cam4.5144

Internet

https://doi.org/10.1002/cam4.5144

Similar Items